Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Aap Implantate AG    AAQ   DE0005066609


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

aap Implantate : is granted European patent for its innovative resorbable magnesium implant technology

share with twitter share with LinkedIn share with facebook
share via e-mail
07/22/2019 | 04:20am EDT

DGAP-News: aap Implantate AG / Key word(s): Patent
aap is granted European patent for its innovative resorbable magnesium implant technology

22.07.2019 / 10:14
The issuer is solely responsible for the content of this announcement.

aap Implantate AG ("aap") announces that it was recently granted a further key European patent for its innovative magnesium implant technology. The patent (EP 2 593 152 B1) describes and protects the process by which aap's magnesium implants are coated. The European patent will now be nationalised in numerous key European markets and published in different languages.

With its resorbable magnesium implant development project aap aims to develop implants that degrade biologically in the body after a successful healing of the fracture or defect, thereby making a second operation to remove the implant unnecessary. The implant must have good biomechanical properties for stabilising and healing the bone and at the same time be resorbable in the patient's body. The implants are small screws and plates consisting of a magnesium alloy and are coated with hydroxyapatite by means of a plasma electrolytic oxidation (PEO) process. The hydroxyapatite coating serves to control the implant's corrosion rate (speed of degradation) respectively the hydrogen development associated with the corrosion.

aap's resorbable magnesium implant technology has several unique selling propositions such as cost efficiency as well as good biomechanical properties combined with a moderate and controllable resorption rate. These properties have been proven in several tests with promising results. In addition, the resorbable magnesium implant technology developed by the company has - as a platform technology - a wide range of applications and can be used not only in orthopaedics but also, for example, in areas such as facial surgery, sports medicine or paediatrics.

The magnesium implant technology addresses a big cost saving potential in the healthcare industry and therefore offers aap a considerable market potential. aap aims in a first step for the US market for mini and small fragment plates with an estimated volume of around US$ 0.6 bn. The global market volume is estimated to about US$ 1.3 bn. aap plans to push forward the further development of its magnesium implant technology jointly with partners under aap's management.


Implantate AG (ISIN DE0005066609) - Prime Standard/Regulated Market - All German stock markets -

About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ(R) and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact:

aap Implantate AG; Fabian Franke; Investor Relations; Lorenzweg 5; 12099 Berlin, Germany;
Tel.: +49/30/750 19 - 134; Fax.: +49/30/750 19 - 290; f.franke@aap.de

22.07.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 844527

End of News DGAP News Service

844527  22.07.2019 


© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AAP IMPLANTATE AG
08/14AAP : Q2/2019 sales and EBITDA in line with guidance; double-digit sales growth ..
08/13AAP IMPLANTATE : adjusts outlook for financial year 2019
08/08AAP IMPLANTATE : receives BfArM approval for human clinical study and becomes gl..
08/08AAP IMPLANTATE : receives BfArM approval for human clinical study for its antiba..
08/06AAP IMPLANTATE AG : Preliminary announcement of the publication of financial rep..
07/22AAP IMPLANTATE : is granted European patent for its innovative resorbable magnes..
07/12AAP IMPLANTATE : receives US-American approval (FDA) for polyaxial LOQTEQ(R) VA ..
07/09AAP IMPLANTATE : will discontinue parts of its standard trauma business at the e..
07/04AAP : Dr. med. Nathalie Krebs elected as new Supervisory Board Chairwoman
06/03AAP IMPLANTATE AG : Application for change within regulated market from Prime St..
More news
Financials (EUR)
Sales 2019 11,0 M
EBIT 2019 -6,70 M
Net income 2019 -6,85 M
Finance 2019 2,10 M
Yield 2019 -
P/E ratio 2019 -3,72x
P/E ratio 2020 -8,56x
EV / Sales2019 2,32x
EV / Sales2020 1,66x
Capitalization 27,6 M
Duration : Period :
aap Implantate AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AAP IMPLANTATE AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 2
Average target price 2,20  €
Last Close Price 0,86  €
Spread / Highest target 180%
Spread / Average Target 157%
Spread / Lowest Target 134%
EPS Revisions
Bruke Seyoum Alemu Chairman-Management Board & CEO
Biense Thomas Visser Chairman-Supervisory Board
Marek Hahn Chief Financial Officer
Rubino di Girolamo Member-Supervisory Board
Jacqueline P. Rijsdijk Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC11.86%136 463
TERUMO CORP-45.97%23 173